News

Podcast

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Author(s):

Alexandra Gerlach, Associate Editor

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: kitsawet | stock.adobe.com
Related Content
ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access
July 10th 2025

ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO Alana Hippensteele, Lead Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Breast cancer cell | Image Credit: © Mopic - stock.adobe.com
July 9th 2025

Obesity-Linked Exosomes May Drive Tumor Aggressiveness in Triple-Negative Breast Cancer

Alexandra Gerlach, Associate Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Steroids -- Image credit: Cozyta | stock.adobe.com
July 9th 2025

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Gillian McGovern, Associate Editor
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
July 9th 2025

Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies

Jennifer D. Goldman, PharmD, CDE, BC-ADM, FCCP Alana Hippensteele, Lead Editor